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Abstract
Background/Purpose The present study attempted to repli-
cate our previous finding that depressive symptoms are a risk
factor for mortality in stable chronic obstructive pulmonary
disease(COPD),but ina different populationwitha different
measure of depressive symptoms. We further investigated
whether type D personality is associated with mortality in
patients with COPD and whether it explains any relationship
observed between depressive symptoms and mortality.
Methods In 122 COPD patients, mean age 60.8±10.3 years,
52% female, and mean forced expiratory volume in 1 s
(FEV1) 41.1±17.6%pred, we assessed body mass index, post
bronchodilator FEV1, exercise capacity, depressive symp-
toms with the Hospital Anxiety and Depression Scale, and
type D with the Type D Scale.
Results In the 7 years follow-up, 48 (39%) deaths occurred.
The median survival time was 5.3 years. Depressive symp-
toms (hazard ratio=1.07, 95% confidence intervals=1.00–
1.14) were an independent risk factor for mortality. Type D
was not associated with mortality.
Conclusions We can rule out type D as an explanation for
the relationship between depressive symptoms and mortal-
ity observed in this sample. However, ambiguity remains as
to the interpretation of the value of depressive symptoms in
predicting death.
Keywords Cardiovasculardisease.COPD.Depression.
TypeDpersonality.Survival.Riskfactors
Introduction
Studies increasingly report that both depression and trait
negative affectivity (NA) predict poor health outcomes,
especially in coronary heart disease (CHD) [1–5]. In
particular, associations between depression and all-cause
mortality have been found in general community samples
[6], as well as in persons with coronary heart disease,
diabetes mellitus, and hypertension [7–11]. The prevalence
of depressive symptoms in patients with chronic obstructive
pulmonary disease (COPD) varies from 6% to over 60%
[12–14], with most studies indicating prevalence well over
20% [15]. Therefore, the prognostic value of depressive
symptoms for health status and survival among patients
with COPD needs more attention than it has yet received.
COPD and Mortality
In COPD, most studies examining prognostic factors for
mortality focus on single physiological variables. Mortality
has been found to be predicted by airflow limitation,
hypercapnia, hypoxemia, more severe dyspnea, low body
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Philadelphia, USAmass index (BMI), and low exercise capacity [16–23]. In
addition, the BODE index, a multidimensional ten-point
scale consisting of graded scores of BMI, airflow obstruc-
tion, dyspnea, and exercise capacity is considered a
valuable tool for predicting the risk of death in patients
with COPD [24, 25].
To our knowledge, only two studies have demonstrated
that symptoms of depression are associated with mortality in
patients with COPD after hospitalization, independent of
disease severity and other risk factors [26, 27]. These studies
were carried out among patients with COPD shortly after
they were hospitalized for acute exacerbation. Depression
symptoms were assessed during hospitalization or immedi-
ately after discharge (2–4 weeks). The recent exacerbation
could well have increased both the self-reported depressive
symptoms, as well as conveyed increased mortality,
introducing an important confound in any apparent associ-
ation between depressive symptoms and death.
In clinically stable COPD, the association between
depressive symptoms and mortality has been less clear.
Two studies did not find an association after adjusting for
disease severity [28, 29] and only one study demonstrated
that adjusted depressive symptoms were associated with
3-year mortality and not with 1-year mortality in stable
COPD [30]. However, we recently demonstrated, in a
different cohort than the sample in the present study, that, in
patients with stable COPD, symptoms of depression,
assessed with the Beck Depression Inventory (BDI), were
a prognostic factor for mortality, independent of age, sex,
and exercise capacity (hazard ratio=1.93, 95% confidence
intervals [95%CI]=1.12–3.33) [31]. While the study
seemed to establish depressive symptoms as predictor of
mortality over a relatively long period of time, ranging from
88 days to 7.8 years, there remains ambiguity in the
explanation for our finding.
The Distressed Personality (Type D)
Denollet and his coworkers suggested that depression is
related to underlying broader and more stable personality
traits, which may explain individual differences in distress
and mortality in patients with cardiovascular disease [32–
34]. Denollet and his coworkers reported in several studies
on “the notion that a general tendency to experience
emotional and interpersonal difficulties may exacerbate
progression of heart disease, irrespective of the diagnosis of
depression or anxiety disorder,” which is the core of the
“distressed (type D) personality” [35, page 949]. In an
attempt to emphasize the role of normal personality
characteristics rather than psychopathology, the “distressed
(type D) personality” was constructed of two specific,
nonpathological traits: NA (the tendency to experience
negative emotions) and social inhibition (SI; the tendency
to inhibit the expression of these emotions in social
interaction). In research on coronary heart disease, type D
is associated with increased risk of depression, vital
exhaustion, social alienation, a high number of reinfarc-
tions, and higher mortality, independently of traditional
biomedical risk factors [36–38]. It is noteworthy that, for
patients with COPD, there is strong evidence for cardio-
vascular comorbidity and mortality, with estimates up to
42% [39–41]. Moreover, to our knowledge, no studies have
been done on the impact of type D on mortality in patients
with COPD or any other chronic medical conditions besides
cardiovascular diseases. Because of the relationship ob-
served between depression and mortality, type D may offer
an explanation in COPD as well.
Hence, the first aim of the present study was to attempt
to replicate in a different population, with a different
measure of depressive symptoms, earlier findings, includ-
ing our own, on the association of depression symptoms
and all-cause mortality in patients with stable COPD. We
adjusted for known risk factors, such as age, forced
expiratory volume in 1 s (FEV1) %pred, exercise capacity,
BMI, and smoking behavior. The second aim was to
examine if the presence of distressed personality (type D)
is a prognostic factor for mortality in patients with COPD
and, by doing so, explore a possible explanation for the
association between depressive symptoms and mortality.
Methods
Subjects
Our study sample consisted of 122 consecutive patients
with stable COPD (FEV1<80% predicted), diagnosed
according to the ATS guidelines [42], who were referred
for pulmonary rehabilitation within a period of 2 years. All
patients were clinically stable for at least 6 weeks and did
not require increase in medication or hospitalization.
Exclusion criteria were inability to perform lung function
and/or ergometry, refusal to fill out psychological ques-
tionnaires, and the presence of comorbidity which limits
prognosis such as malignancy or severe heart failure.
Measurements
Patient Characteristics
Uponadmission,demographicdata,suchassexandage,were
recorded. Marital status was dichotomized in terms of living
witha partner versus livingwithout a partner. Patients without
a partner included those patients who were widowed,
divorced, or never married. Smoking behavior was assessed
by a self-report questionnaire and defined in three categories:
ann. behav. med. (2009) 38:86–93 87(1)neversmokedcigarettes(NS),(2)cessationofsmokingfor
1y e a ro rm o r e( E S ≥1 year), and (3) current smoker (CS) or
cessation of smoking less than 1 year (ES<1 year).
Depression
Depressive symptoms were assessed with the depression
subscaleoftheHospitalAnxietyandDepressionScale(HADS)
[43, 44]. The HADS is a validated and reliable psychological
measure and it is widely used in medically ill populations.
This 14-item self-report screening scale was developed to
indicate the presence of anxious and depressive states. The
depression subscale has seven items and total score range
from 0 to 21, with a higher score indicating more pathology.
In the present paper, we studied depressive symptoms and not
major depressive disorder. To facilitate interpretation and
comparison with others’ data, we also analyzed depressive
symptoms using the conventional cut-off level of ≥8t ol a b e l
patients in high and low depressive symptoms distinction.
Type D Personality
A distressed personality (type D) was assessed by the Type
D Scale (DS16), a brief self-report measure comprising of
an eight-item NA scale, which assesses the tendency to
experience negative emotions, and an eight-item SI scale,
which assesses the tendency to inhibit the expression of
these emotions in social interaction [37]. Consistent with all
past studies, these continuous variables were dichotomized
using the same cut-off as the Denollet study, which were
based on a median split of the NA and SI scales in his
study. Patients with a distressed personality or type D
reported high levels of NA (≥10) and SI (≥15).
Physiological Parameters
The BMI is weight in kilograms divided by the square of the
body height in meters. Airflow obstruction was established by
the FEV1, post bronchodilator, expressed in liters and as
percentage of the predicted value and was assessed according
to ATS standards (Jaeger Masterlab 4.521). Exercise capacity
(Wpeak) was defined as the highest workload reached and
maintained for at least 30 s during a symptom-limited
incremental cycle ergometry (Oxycon pro, Viasys Healthcare)
[45]. A protocol with 5 or 10 W/min increment in load was
applied depending on the estimated Wpeak, starting with 1 min
of unloaded pedaling and aiming at a duration of 6–12 min.
Mortality
The vital status of these patients was ascertained on 1st of
April 2007 using municipal registrations. The rationale for
relying on all-cause mortality was that clinical assessments
of cause of death are difficult, often incorrect and always
involve a subjective component [46].
Statistical Analysis
All analyseswereperformedusingSPSSforWindows (SPSS,
Chicago, IL, USA). All 122 patients were included in the
analyses. Continuous variables are presented as means and
standarddeviations,exceptforfollow-uptime,wheremedians
were presented. Dichotomous variables are presented as
percentages. Surviving and nonsurviving patients were com-
pared using independent t test for continuous variables and
Fisher’s exact test for dichotomous variables. The relations
among the variables were analyzed using Pearson’sc o r r e l a -
tions for continuous variables and Spearman’sc o r r e l a t i o n s
for ordinal variables (e.g., smoking). Bivariate hazard ratios
associated with each possible predictor variable for mortality
were examined. Multivariate Cox proportional hazard anal-
yses with all variables entering in a single step in the model
with backward stepwise selection, backward stepwise
(Wald), were used to quantify the relationship between
baseline variables and mortality and 95%CI were estimated
with significance at p<0.05. On a multivariate level, we
analyzed whether type D adds to the model or whether type
D is associated with mortality independent of age, FEV1 %
pred, and Wpeak. High/low depressive symptoms were plotted
in survival curves using Kaplan–Meier estimates.
Results
Characteristics of our study sample (63 women and 59
men) on the whole and according to their vital status are
presented in Table 1. Correlations among the key predictor
variables are presented in Table 2. The average age was
60.8±10.3 years and the post bronchodilator FEV1 %pred
was 41.1±17.6.
The mean score was 6.3±4.2 on the HADS depression
scale. A third of the patients (33%) tested above the
standard cut-off score and can be classified as having
substantial depressive symptoms. Survival time varied from
21 days to 7 years (median=5.3 years). For the 122 patients,
1-year mortality was 5 (4%), 2-year mortality was 12 (10%),
3-year mortality was 24 (20%), 4-year mortality was 33 (27%),
5-year mortality was 41 (34%), and 6-year mortality was 48
(39%). The rate of death differed between high depressive
symptoms patients (21/40=53%) and low depressive symp-
toms patients (27/82=33%), chi square p=0.04. Other signif-
icant differences between survivors and nonsurvivors were
that survivors tested a larger FEV1 expressed in liters and as
percentage of predicted value and more exercise capacity
(Wpeak). Differences on sex, marital status, smoking behavior,
BMI, and type D were not significant. Depressive symptoms
88 ann. behav. med. (2009) 38:86–93were correlated with younger age (r=−0.18), current
smoking or having quitted smoking less than a year (r=
0.21), type D (r=0.49), and both DS16 subscales NA (r=
0.74) and SI (r=0.36).
Table 3 shows the unadjusted and adjusted Cox
proportional hazards analyses. On a bivariate level, having
a lower FEV1 %pred (hazard ratio=0.95, 95%CI=0.93–
0.97), a lower exercise capacity (Wpeak; hazard ratio=0.97,
95%CI=0.95–0.98), and having more symptoms of depres-
sion (hazard ratio=1.08, 95%CI=1.01–1.15) are signifi-
cantly related to mortality in patients with COPD in our
sample. Also, the dichotomous variable low/high depres-
sive symptoms (hazard ratio=1.96, 95%CI=1.11–3.47) was
found to be significantly related to mortality. However, sex,
age, marital status, smoking behavior, BMI, and type D nor
one of the subscales of the DS16 (i.e., NA and SI) were
associated with mortality. Multivariate analysis demon-
strates that depressive symptoms (hazard ratio=1.07, 95%
Table 2 Correlations between the variables (N=122)
Variable 1 2 3 4 5 6 7 8 9 10
1. Sex
a 1
2. Age 0.09 1
3. Partner 0.38** 0.11 1
4. Smoking
b −0.15 −0.32** −0.15 1
5. FEV1 (%pred) −0.06 0.03 −0.01 −0.17 1
6. BMI 0.08 0.19* −0.05 −0.23** 0.43** 1
7. Wpeak 0.17 −0.28** 0.16 −0.06 0.57** 0.22* 1
8. Depressive symptoms −0.13 −0.18* −0.15 0.20* −0.12 −0.12 −0.16 1
9. NA −0.14 −0.28** −0.16 0.06 −0.10 −0.13 −0.09 0.74** 1
10. SI −0.23* 0.11 −0.06 0.09 0.02 −0.11 −0.13 0.36** 0.30** 1
11. Type D 0/1 −0.14 −0.06 −0.09 0.06 −0.06 −0.12 −0.07 0.49** 0.61** 0.51**
All correlations are Pearson correlations, except for ordinal variables (smoking) Spearman’s correlations were used
0/1 no/yes
*p<0.05; **p<0.01
a0=female, 1=male
b0=NS, 1=ES≥1 year, 2=ES <1 year or CS
Variable All patients Survivors All-cause mortality p value
a
Median f.u. time (years) 5.3 5.8 3.0
Female sex (%) 52 49 56 ns
Age (years) 60.8 (±10.3) 59.6 (±11.6) 62.8 (±7.7) 0.07
Partner yes (%) 66 68 65 ns
Smoking (%) ns
NS 8 10 6
ES ≥1 year 57 58 54
CS or ES <1 year 35 33 40
FEV1 (l) 1.17 (±0.60) 1.4 (±0.6) 0.9 (±0.4) <0.001
FEV1 (%pred) 41.1 (±17.6) 47.1 (±17.3) 31.9 (±13.9) <0.001
GOLD stages (%)
II/III/IV 27/41/32 39/45/16 8/35/56
BMI (kg/m
2) 25.8 (±5.9) 25.7 (±5.1) 25.9 (±7.1) ns
Wpeak (W) 50.1 (±32.5) 62.3 (±32.4) 31.3 (±22.0) <0.001
Depressive symptoms 6.3 (±4.2) 5.8 (±4.2) 7.2 (±4.0) 0.06
High depressive symptoms (%) 33 26 44 <0.05
NA (DS16) 10.1 (±6.7) 10.0 (±7.2) 10.2 (±5.8) ns
SI (DS16) 14.8 (±6.4) 14.6 (±7.0) 15.1 (±5.5) ns
Type D (%) 29 28 29 ns
Table 1 Characteristics of the
sample COPD patients (N=122)
All patients (N=122, survival
61%) were included in the
analyses
NS never smokers, ES ≥1 year
ex-smoker for 1 year or more,
CS or ES <1 year current
smoker or ex-smoker for less
than 1 year
aIndependent samples t test for
continuous variables and
Fisher’s exact test for
dichotomous variables.
Survivors versus all-cause
mortality; ns not significant
(p>0.1)
ann. behav. med. (2009) 38:86–93 89CI=1.00–1.14) are significantly associated with mortality
when adjusted for age, FEV1 %pred, and Wpeak. When
using the adjusted dichotomous low/high depressive symp-
toms, based on the cut-off level of ≥8, again, we found a
significant association with mortality (hazard ratio=1.98,
95%CI=1.07–3.69). This is illustrated in Fig. 1 in which
the Kaplan–Meier survival curves are shown for the high
and low depressive symptoms groups. Sex, marital status,
smoking behavior, BMI, and type D were also included but
were later removed from the model because they failed to
reach statistical significance. We did not find any interac-
tion effects.
The prevalence of the distressed personality (type D) in
our sample was 29%. Type D and each subscale considered
separately, NA and SI, did not differ significantly between
survivors and nonsurvivors. The rate of death did not differ
between type D patients (14/35=40%) and nontype D
patients (34/87=39%), chi square p=0.93. Furthermore,
type D was not associated with any of the other predictor
variables, except for, as earlier mentioned, depressive
symptoms (r=0.49).
Given the finding that depressive symptoms correlate 0.49
with type D and yet type D was not related to mortality, we
undertook a number of exploratory analyses. We tested
whether type D was associated with mortality when adjusted
for age, FEV1 %pred, and Wpeak. This multivariate analysis
shows that type D was not associated with mortality. Next,
we looked at both the components NA and SI in relation to
depressive symptoms. The correlation between depressive
symptoms and NA is 0.74, as high as the reliabilities of the
two scales would allow. However, it is notable that the type
D concept involves being above the median splits of both
NA and SI subscales. This both excludes 16 patients with
substantial depressive symptoms because they did not meet
the cut-off on the SI subscale (or the NA subscale) and
included 11 patients with relatively low numbers of
depressive symptoms who met both cut-off points.
Discussion
This study provides further evidence that depressive
symptoms, independent of age, lung function, and exercise
capacity, are prognostic factors for mortality in COPD. We
found that type D personality is associated with depressive
symptoms, but despite this moderate association, type D
itself is not a prognostic factor for mortality in COPD.
Two previous studies in samples of patients with COPD
who were hospitalized because of a recent exacerbation
demonstrated that symptoms of depression were associated
with mortality independent of disease severity and other risk
Bivariate Multivariate
Hazard ratio 95%CI Hazard ratio 95%CI
Sex (0=female) 0.79 0.45–1.40
Age (years) 1.03 1.00–1.05 1.03 1.00–1.08*
Partner (0=no) 0.85 0.47–1.54
Smoking
a 1.21 0.76–1.92
FEV1 %pred 0.95 0.93–0.97*** 0.96 0.94–0.99**
BMI 1.00 0.95–1.05
Wpeak 0.97 0.95–0.98*** 0.98 0.96–1.00*
Depressive symptoms 1.08 1.01–1.15* 1.07 1.00–1.14*
Depressive symptoms (0=low) 1.96 1.11–3.47* 1.98 1.07–3.69*
NA 1.01 0.96–1.05
SI 1.01 0.97–1.06
Type D (0=no) 1.03 0.55–1.91
Table 3 Predictors for mortality
in COPD patient, Cox propor-
tional hazard model backward
stepwise (Wald) method
*p<0.05, **p<0.01,
***p<0.001
a0=NS, 1=ES ≥1 year,
2=CS or ES <1 year
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Fig. 1 Kaplan–Meier survival curves for COPD patients with separate
lines for high and low depressive symptoms (adjusted for covariates
age, FEV1 %pred, and exercise capacity)
90 ann. behav. med. (2009) 38:86–93factors [26, 27]. It has been argued that the possibility should
be considered that these results may be a consequence of the
difficulties of distinguishing affective dispositions from
patients’ medical conditions [47]. However, one past study
found a similar effect in patients with clinically stable COPD
[30]. Moreover, in another recent study, we were able to
obtain this result in a group of patients with clinically stable
COPD in pulmonary rehabilitation. A similar association
was found between depressive symptoms, assessed with the
BDI and mortality, independent of sex, age, and exercise
capacity [31]. It is noteworthy that our finding was in a
population of patients with stabilized COPD. Unlike some
recent studies in which the assessment of depressive
symptoms was following a recent exacerbation of COPD,
our results are less obviously the product of a spurious
relationship between depressive symptoms and mortality due
to a confounding with physical distress that anticipates death.
Our median follow-up period was also longer than would be
affected by acute illness.
Some sources have argued that, in the assessment of
depressive symptoms in patients with cardiovascular dis-
ease, scores obtained with instruments like the widely used
BDI are inflated among patients with medical disease
because of the confounding of vegetative symptoms [48–
50]. The HADS is constructed to avoid assessment of
somatic symptoms. Still, in the present study, despite the
use of a different instrument to assess depressive symp-
toms, the HADS, we found a similar effect of depressive
symptoms on mortality. The fact that the depression–
mortality association is consistent in two different groups
of patients with stable COPD and with two different
assessment tools for symptoms of depression, i.e., BDI
and HADS, strengthens the evidence for this relation and
adds to the established predictor variables.
With regard to the association of depressive symptoms
and mortality, two hypothetical pathways are suggested.
One may be through behavioral mechanisms such as that
depression leads to low self-care and apathy resulting in
avoidance of regular exercise, inadequate nutritional intake,
low treatment adherence, and continued smoking, all of
which are related to worse prognosis. Another pathway
may be that depression affects the hypothalamic pituitary
adrenal axis functioning which could deteriorate health
status and influence prognosis [51–53]. Evidence is
consistent that inflammation occurs among a subset of
depressed patients and thus may worsen prognosis in
COPD [54]. Still, the depression–mortality relation may
still be confounded by other unmeasured factors related to
both depressive symptoms and mortality, namely, overall
chronic disease burden [55].
Regardless, depressive symptoms represent a burden for
patients because of its influence on their quality of life.
Elderly persons reporting depressive symptoms are partic-
ularly at risk of chronic decline of health [56]. Several
studies have reported that major depression is reduced by
psychological or antidepressant interventions [57]. Also,
pulmonary rehabilitation has been known to reduce
depression and improve quality of life [58–60]. Moreover,
pulmonary rehabilitation is even potentially beneficial in
reducing the risk of mortality [61]. However, there are no
studies yet that have established if decrease of depression
symptoms in patients with COPD actually reduces the risk
for mortality.
In cardiovascular research, Denollet and his coworkers
offered type D personality as an explanation of the
observed association between depressive symptoms and a
variety of cardiovascular outcomes [33, 38, 62]. Although
there is evidence for substantial comorbidity between
COPD and cardiovascular disease, with smoking and
airflow limitation as independent risk factors for mortality
[39–41], we did not find that the presence of type D
personality was related to mortality at a bivariate level nor
in a multivariate model. While type D is correlated with
symptoms of depression, it is apparently not a factor which
could explain the depression–mortality relation in COPD.
Perhaps, although unlikely, type D is specifically associated
with cardiovascular morbidity and death.
On the other hand, we have already noted the moderate
correlation between depressive symptoms and type D, but
that depressive symptoms have a high correlation with one
of the components, namely, NA. Use of median splits then
to construct typology resulted in some high depressive
patients being excluded and some relatively low in
depressive symptoms, but still above the median split,
being included. Also, Suls and Bunde have presented their
concerns on the degree of overlap among different affective
dispositions [47]. The degree of overlap may provide a
partial explanation for inconsistencies in our study. Despite
the high correlation between NA and depressive symptoms,
our null effect in the type D mortality association may be a
consequence of minimal overlap with the cardiotoxic affect.
However, we agree with Suls and Bunde that it is unlikely
that this is the sole explanation for the inconsistency [47].
In another context, Maxwell and Delaney have cautioned
about the likelihood of spurious results when a typological
construct, like type D, is created from two dichotomized
variables:
When two (or more) continuous predictor variables
are dichotomized, the resulting 2×2 analyses are not
necessarily conservative. Instead, there is a potential
for an effect that is truly zero for a continuous
measure to be estimated as a small to medium effect
in the 2×2 factorial design [63, p. 188].
The present results thus offer no support for pursuing
type D as an explanation for COPD mortality. However, it
ann. behav. med. (2009) 38:86–93 91could be important to examine the potential statistical
problems with type D construct in cardiovascular disease.
Some limitations of this study should be noted. First,
data on the nature and numbers of comorbid conditions
were not consistently recorded and, therefore, not included
in the study. These data, especially on cardiovascular
comorbidities, could have provided us with additional clues
on a possible explanatory mechanism of the association
between depressive symptoms and mortality and/or the null
finding with regard to the type D–mortality association.
Second, the cause of death was not determined. Variables in
our study are prognostics for all-cause mortality and not
just for respiratory causes. However, in studies of all-cause
mortality, the actual cause of death is not independently
validated and known to be less trustworthy [46]. Third, our
study includes several potential modifiable variables, such
as smoking behavior, BMI, FEV1, and exercise capacity,
which may alter in time. In COPD, patient reported
outcomes on health status, dyspnea, and psychological
status, as well as physiological outcomes deteriorate over
time, but intercorrelations between both types of outcomes
are weak [64]. In our study, assessment of depressive
symptoms was limited to a single point in time. This
assessment leaves unexplored questions about the stability
and course over time. However, we believe our assessment
allows demonstration of the predictive value of depressive
symptoms in COPD. Finally, we observed our findings
among patients with clinically stable COPD, which perhaps
limits generalization to all patients with COPD. However,
taken together with findings of the other studies demon-
strating the predictive value of depressive symptoms in
COPD, our results give support to further studies on the
course of depressive symptoms in relation to mortality.
In conclusion, the present paper provides further
evidence for the association of depressive symptoms and
mortality. This association may very well reflect confound-
ing by other unmeasured factors [55]. In this study, we did
not find that the presence of type D personality is related
mortality or that it is a confounder in the depression–
mortality relationship in patients with COPD. In contrast to
cardiovascular disease, it seems that we can rule out type D
as an explanation for the relationship between depressive
symptoms and mortality observed in this sample. Further
efforts are encouraged to disentangle the relationships
found, and more attention should be paid to behavioral
and physiological mechanisms.
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